## **REMARKS**

Currently claims 1-11 are pending. Applicants have attached an abstract on a separate sheet of paper as required by US practice, and have amended the specification for purposes of adding the priority information.

Respectfully submitted,

Michael M. Conger


Attorney for Applicants Registration No. 43,562

Date: October 11, 2004

GlaxoSmithKline Inc.

Corporate Intellectual Property Five Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709

Phone: 919-483-2474 Facsimile: 919-483-7988 PU4825USw



## COMPOSITIONS AND METHODS FOR EVALUATING AND DESIGNING NUCLEAR RECEPTOR LIGANDS THAT MODULATE CO-REGULATOR AFFINITY

## Abstract of the Disclosure

Isolated corepressor peptides derived from a nuclear receptor interacting motif of corepressor Nuclear Receptor Corepressor (NCoR) or Silencing Mediator of Retinoid and Thyroid receptors (SMRT) are provided which binds to nuclear receptor ligand binding domains. Methods of using these peptides to evaluating selectivity of a ligand for a nuclear receptor subtype and quantitatively profiling selectivity of a test compound for a nuclear receptor are also provided.